Imfinzi and Enhertu has trial data highlighted in the ASCO plenary session — an occasion AstraZeneca executives are marking with a pin that weaves the number “7” between the “A” and “Z” of their ...

WILMINGTON, Del., June 01, 2025--(BUSINESS WIRE)--Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI ® (durvalumab) in combination ...

Imfinzi combined with FLOT chemotherapy improved EFS in resectable gastric/GEJ adenocarcinoma, with no new safety signals observed. Adverse effects were comparable between Imfinzi and placebo arms, ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to results from a phase 3 study. Adding Imfinzi to the chemotherapy regimen ...

Two-thirds (67.4%) of patients treated with IMFINZI-based perioperative regimen remained event-free at two years First and only immunotherapy to demonstrate statistically significant event-free ...

Recommendation based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) announced today that its drug Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as a treatment for adult patients with ...

Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI ® (durvalumab) in combination with standard-of-care FLOT (fluorouracil ...

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that its Imfinzi (durvalumab) has been recommended for approval in the European Union to treat muscle-invasive ...